Aptus Pharma IPO Details
Aptus Pharma IPO Summary
Aptus Pharma IPO opens for subscription on 23 Sep 2025 and closes on 25 Sep 2025.The IPO will be listed on BSE with the tentative listing date set for 30 Sep 2025.
Aptus Pharma IPO price band has been fixed at ₹65 – ₹70 per share. The face value is ₹10 per share with a lot size of 2000.
Aptus Pharma IPO total issue size comprises 18,60,000 shares (aggregating up to ₹13.02 Cr). This includes a fresh issue of 18,60,000 shares (aggregating up to ₹13.02 Cr). Pre-issue shareholding stands at 50,00,000, which will increase to 68,60,000 post-issue.
Aptus Pharma IPO carries a ₹4 (5.71%) GMP, reflecting investor sentiment.
Aptus Pharma IPO Lot Size :Individual Minimum is 2 lots (4,000 shares) amounting to ₹280,000. Individual Maximum is 2 lots (4,000 shares) amounting to ₹280,000. SHNI Minimum is 3 lots (6,000 shares) amounting to ₹420,000. SHNI Maximum is 7 lots (14,000 shares) amounting to ₹980,000. BHNI Minimum is 8 lots (16,000 shares) amounting to ₹1,120,000.
The Lead Managers for Aptus Pharma IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Interactive Financial Services Ltd. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.
For SME (Small and Medium-sized Enterprise) IPOs, a Market Maker is appointed to ensure liquidity and stability for the stock once it is listed. They do this by continuously quoting bid and ask prices, ensuring there is a market for the shares. The appointed market maker for this IPO is Market-Hub Stock Broking. You can analyze their track record by checking the Market Maker Performance Summary report.
For detailed information, Refer to the Aptus Pharma Limited RHP.
Aptus Pharma IPO Details
Aptus Pharma IPO Subscription
Aptus Pharma IPO Application Wise Breakup
Aptus Pharma IPO Dates
- 23 Sep 2025Opening dateOpen
- 25 Sep 2025Closing dateClose
- 26 Sep 2025Allotment Date Allotment
- 29 Sep 2025Initiation of RefundsRefund
- 29 Sep 2025Credit of SharesCredit
- 30 Sep 2025Listing dateListing
Aptus Pharma IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual Minimum | 2 | 4000 | ₹280,000 |
| Individual Maximum | 2 | 4000 | ₹280,000 |
| SHNI Minimum | 3 | 6000 | ₹420,000 |
| SHNI Maximum | 7 | 14000 | ₹980,000 |
| BHNI Minimum | 8 | 16000 | ₹1,120,000 |
Aptus Pharma IPO Reservation
Promoter Holding
Documents
Aptus Pharma IPO Valuations
Aptus Pharma Financial Information
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
| Assets | 21.92 | 10.03 | 6.22 |
| Total Income | 24.64 | 17.88 | 13.90 |
| Profit After Tax | 3.10 | 0.80 | 0.19 |
| EBITDA | 4.76 | 1.49 | 0.57 |
| Net Worth | 6.97 | 1.77 | 0.97 |
| Reserves and Surplus | 1.97 | 1.47 | 0.67 |
| Total Borrowing | 10.36 | 5.31 | 2.21 |
| Amount in ₹ Crore | |||
About Aptus Pharma IPO
Aptus Pharma manufactures and distributes a broad range of pharmaceutical formulations covering multiple therapeutic areas: antacids & PPIs, pain management, anti-inflammatories, antibiotics, cardiology & antidiabetics, neuropsychiatry, dental, injectable parenterals, syrups, nutraceuticals, sachets, and more.
Products:
- Aptus Pharma: Focuses on acute therapies i.e, anti-infectives, pain management, etc.
- Aptus CD care: Focused on chronic therapies
- Aptus Wellcare: Offers wellness and nutraceutical products
- Aptus Global: Export in overseas market
As of March 31, 2025, the company has 194 pharmaceutical formulations in more than eleven therapeutic segments.
Its warehouse is located over 15,732 sq. Feet and 1989 sq. feet in Ahmedabad, Gujarat. Its distribution model includes 125 direct and sub distributors and a sales team of 54 field personnel.
Strength Of Aptus Pharma IPO
1. Diversified Product Portfolio.
2. Robust and Responsive Distribution Network.
3. Strategic Manufacturing Partnerships.
4. Commitment to High-Quality Standards.
5. Competitive and Cost-Effective Pricing.
6. Skilled and Committed Human Resources.
7. Experienced and Visionary Management Team.
8. Customer Satisfaction and Retention.
Risk Of Aptus Pharma IPO
1. We do not have our own manufacturing facility for pharmaceutical products and we have to rely on third parties for contract manufacturing of the products sold by our Company.
2. We are required to obtain, renew or maintain certain material statutory and regulatory permits and approvals required to operate our business, and if we fail to do so in a timely manner or at all, we may be unable to operate our business and our results of operations may be adversely affected.
3. We derive a significant part of our revenue from few customers. If one or more of such customers choose not to source their requirements from us or to terminate our contracts or purchase orders, our business, cash flows, financial condition and results of operations may be adversely affected.
4. If we are unable to protect our intellectual property rights, our business, results of operations and financial condition may be adversely affected. Further, if our products were found to be infringing on the intellectual property rights of a third-party, we could be required to cease selling the infringing products, causing us to lose future sales revenue from such products and face substantial liabilities for infringement of intellectual property rights.
5. Our Company may be exposed to product liability and other claims arising from defective medicines manufactured by third-party Contract Manufacturers, despite having manufacturing agreements in place, as indemnity terms are not pre-determined.
6. We are highly dependent on the medical practitioners including general physicians, paediatricians, gynaecologists, cardiologists, endocrinologists, neurologists, and others. Any disruption in such understanding may adversely impact our business operations.
7. Our business is working capital intensive. If we are unable to borrow to meet our working capital requirements, it may materially and adversely affect our business and results of operations.
8. We have had negative cash flows from operating activities in the last three Fiscal years and may continue to have negative cash flows in the future which could have an impact on our business and operations.
9. Our Company does not have intellectual property rights over its corporate logo. In absence of our Registered Logo or Trademark there are chances of getting damage to our business prospects, reputation and goodwill and misuse of our logo.
10. There have been certain delays in filing of GST, PF/ESIC returns of the company. Consequently, we may be subject to adverse regulatory actions and penalties for any past or future non-compliance and our business, financial condition and reputation may be adversely affected.
Objectives Aptus Pharma IPO
1. Capital Expenditure for Office Premises with furniture and Industrial Racks
2. Working Capital
3. General corporate purposes
Company Contact Details
Aptus Pharma Ltd.
Ashutosh Buildcon, Opp. Slok - 2,
Nr. Harikrupa Logistic Park,
Aslali, Ahmedabad, Daskroi,
Ahmedabad, Gujarat, 382427
Phone: +91 76004 27827
Email: info@aptuspharma.com
Website: https://aptus-pharma.com/
Registrar Contact Details
Aptus Pharma FAQs
The Aptus Pharma IPO is a SME public issue comprising 1860000 equity shares with a face value of ₹10 each, aggregating to a total issue size of ₹13.02 Cr. The issue price has been fixed at ₹70 per equity share, and the minimum application size is 2000 shares.
The IPO opens for subscription on 23 Sep 2025, and closes on 25 Sep 2025.
Bigshare Services Pvt Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the BSE
As of now, the current GMP stands at ₹4 (5.71%).
Quick Links
Comments
